

Keyword Index for Volume 102

- 3-phosphoinositide-dependent protein kinase 1 104
5-fluorouracil 475, 1254, 1483
8-oxodG 1018
- α -tocopheryl succinate 1224
 α -trinositol 833
ABCG2 1276
acoustic neuroma 1654
acquired resistance 383
actomyosin contractility 392
ADCC 520
adenocarcinoma 1692
adenoma 765
adenovirus 796
adipocytes 403
adipose tissue 1541
AdnaTest 276
advanced breast cancer 1341
advanced disease 1687
advanced gastric cancer 475
advanced oesophageal cancer 475
adverse events 80
AEE788 1235
AFP 748
Africa 957
African breast cancer 369
aftercare 1447
Akt 1163
AKT1 1491
alanine aminotransferase 1371
albumin 1113
ALDH1 369
alternative fusion gene 436
Amsterdam II criteria 482
anaemia 301
anaesthesia 1555
anal cancer 1123
angiogenesis 8, 196, 530, 837, 1524, 1592, 1636
angiogenesis inhibitors 268
animal welfare 1555
anoxia 561
anti-angiogenic 495, 594
antibody 500, 827
anti-EGFR therapy 151
anti-neoplastic 1361
anti-TPO antibodies 852
anti-tumour activity 1099
APE1 704, 1600
apoptosis 97, 104, 165, 383, 506, 577, 583, 873, 1010, 1474, 1592, 1707, 1717
arachidonic acid 403
aromatase 1235
AS1402 827
ascorbic acid 1224
Asian continental ancestry group 1438
aspirin 1415
- assessment of treatment response 35
attributable fraction 1428
autotaxin 941
- β 43–63 594
 β -catenin mutation 1032
Barrett's oesophagus 1608
basal-like 369
BC 815
Bcr-Abl 1474
betaine 489
bevacizumab 80, 268, 495, 981, 1468
biliary tract cancer 68, 1185
bilirubin 1371
bioinformatics 1244
biomarkers 8, 268, 361, 462, 1174, 1378, 1524
birth order 1670
birth weight 227
bispecific antibody 124
bisphosphonates 799
BiTE 124
Blacks 1676
bladder cancer 883
BMI-1 369, 892
body mass index 610, 966
bone diseases 651
bone loss 645
bone marrow 403
bone metastasis 332, 457
bone mineral density (BMD) 294, 645
BRAF 151, 1724
BRAF mutations 1762
BRAF oncogene 482
brain 1219
brain metastasis 1213
brain tumour 1786
BRCA1 1061, 1091
BRCA2 1091
BRD8 325
breast cancer 35, 42, 213, 220, 276, 342, 351, 361, 462, 489, 645, 799, 827, 941, 1003, 1010, 1024, 1081, 1099, 1235, 1284, 1294, 1461, 1495, 1503, 1645, 1665, 1736
breast cancer risk 1400
breast imaging 35
breast neoplasms 651, 1391
breast screening 285
brucein D 583
- C1QA 1294
C20orf20 (MRGBP) 325
CA4P 1355
cachexia 665, 833
cancer burden 1428
cancer incidence 620
cancer incidence trends 1411
- cancer screening 1085
cancer stem cell 789
cancer survivors 1085
capecitabine 59, 475, 981, 987, 995, 1468, 1687
carbonic anhydrase IX 1627
carboplatin 1355
carcinoembryonic antigen 124
carcinogenesis 1391, 1428
carcinoma 1533
case-control 615, 799
CCBE1 87
CCSQ-FACIT 59
CD133 1265
CD24 206
CD-31 530
CD44 206
Cdc25A 1361
CDK 342
CECs 268
cell cycle 873
cell flow experiments 602
cell lines 553, 898, 1618, 1769
cell migration 1145
cell proliferation 325
cell-cycle arrest 1578
CellSearch System 276
cellular adhesion 1541
cellular FLICE inhibitory protein (c-FLIP) 754
cervical cancer 23, 196, 933, 1657
cervical screening 933, 1405
cetuximab 162, 500, 520, 1137
chemoradiation 1123
chemoresistance 1717
chemosensitivity 541
chemotherapy 115, 294, 500, 629, 810, 1099, 1106, 1313
childcare 1670
childhood cancer 620, 1670
childhood leukaemia 796
Child–Pugh 748
chimeric protein 436
Chinese 610
CHK1 862
chloride channel 4 774
Choi criteria 803
choline 489
chromosomal translocation 436
chromosome 243
chromosome aberration 1044
CIN 933, 957
circulating biomarker 577
circulating tumour cells 276, 561, 1327, 1495
cisplatin 383, 475
class III β -tubulin 316
clonogenicity 1145
CML 1474
c-myc 892
CNS disease 995
CNS lymphoma 673
- CNS tumour 1670
cohort 489
colon cancer 165, 754, 1145, 1265, 1753
colony survival 1578
colorectal adenocarcinoma 1384
colorectal cancer 48, 59, 151, 162, 325, 447, 506, 765, 774, 908, 916, 972, 1254, 1327, 1519, 1746
colorectal liver metastases 1313
colorectal neoplasms 1468
colorectal tumour 693
combretastatin A4 phosphate 1355
conjunctiva 262
contralateral breast 213
copy number 1378
cost 80
COX-2 916
CRC 1137, 1300
C-reactive protein 1113
CSC 1265
cumulative risk 42
cutaneous melanoma 1213, 1447
cyclin D1 1378
cyclin D1 expression 1762
cyclooxygenase-2 765
cyclophosphamide 1003
cyclophosphamide, vincristine, and prednisone 19
CYP2D6 294
cytarabine 673
cytokeratin 18 577
cytology 933, 1180, 1405
cytolytic killing 124
cytomegalovirus 1665
cytotoxicity 852
- DASL 570
DBC1 1061
DCIS measurement 285
DDC 1384
death receptor 5 (DR5) 754
dendritic cells 115
DHMEQ 206
diagnostic accuracy 48, 181
diagnostic imaging 651
dichloroacetate 1746
differential allelic expression 1294
digalloyl-resveratrol 1361
discrete choice experiment 972
disease-free survival 719
distant relapse 428
DNA arrays 462
DNA damage 862, 1578
DNA methylation 419
DNA ploidy 1608
DNA repair 1018
docetaxel 475
doxorubicin 361, 1003

- drug resistance 1265, 1276, 1636
 drug target 1265
 drug-interaction 1699
 dynamic contrast-enhanced MRI 23
 E17K 1491
 E2F1 protein 1753
 E6/E7 mRNA 957
 early detection 1681
 early growth response gene-1 (Egr-1) 754
 early-stage cervical cancer 1692
 EG3287 541
 EGF 457
 EGFR 144, 165, 500
 EGFR pathway 1778
 ELISA 1524
 EMT 639
 encapsulated follicular thyroid tumour 376
 endometrial cancer 134, 952, 1201
 endothelial 594
 enhanced retroviral mutagenesis 774
 enhancing fraction 23
 epithelial tumours 436
 epithelial-to-mesenchymal transition (EMT) 351, 844, 898
 Epstein-Barr virus 1665
 ERBB 457
 ErbB2/Her2 513
 ERCC1 1600
 ERG/ETV1 gene rearrangements 678
 erlotinib 268
 erythropoiesis-stimulating agent 301
 E-selectin 602
 ethnicity 249
 EWS-Oct-4B 436
 exfoliated cell 916
 exome 243
 expression profile 1769
 extracellular matrix 1541
 faeces 916
 familial breast cancer 42, 1091
 familial risk 1786
 family history 237, 1091, 1676
 fatty acids 1736
 FDG-PET 35
 FGFR3 1145
 fibrinogen 594, 952
 fibroblast 1533
 fibroblast growth factor receptor 188
 fibromatosis 1032
 FISH 1495
 fluorescence in situ hybridisation 678
 Folate receptor α 553
 follicular adenoma 376
 follicular lymphoma 19
 follicular thyroid carcinoma 376
 follow-up 1447
 formylpeptide receptor 1052
 fracture risk 645
 FSCN1 883
 fundamental and translational research 1555
 γ H2AX 1511
 G protein-coupled receptor 941
 gabarapl1 1024
 gallstones 1185
 gastric cancer 237, 500, 665, 710, 738, 1174
 gastro-oesophageal cancers 704, 1600
 Gb3 383
 gene amplification 693
 gene expression 361, 414, 428, 1284, 1636
 gene expression profiling 206
 genetic instability 1300
 genetically engineered mouse models 1555
 genome 243
 genotyping 930
 gestational age 227
 glioblastoma 1052
 GPRD 1415
 grandmaternal age 1400
 GSTP1 987
 GTN 810
 guidelines 645
 haemostasis 594
 HCC 748, 1618
 hCG 810
 head and neck cancer 181, 1687
 health transition 1438
 health-related quality of life 19, 658
 hedgehog signalling pathway 738
 hepatocellular carcinoma 981, 1483
 HER2 815, 1495
 Her2 + metastatic breast cancer 995
 HER2 signalling 1503
 HIF 789
 high-dose chemotherapy 673
 high-grade dysplasia 1608
 histologically normal epithelium 1284
 histone γ H2AX 1578
 HLA1 115
 HNPCC 1068
 HNSCC 1778
 Hospital Discharge Registry 1397
 housekeeping genes 1037
 HPCs 268
 HPV 930, 1657
 HPV DNA 957
 HPV testing 1405
 HPV vaccination 933
 HuHMFG1 827
 human papillomaviruses 262, 1044
 human tumour xenografts 1555
 humane endpoints 1555
 hyperthyroidism 1397
 hypoxia 351, 428, 561, 789
 hypoxia inducible factor (HIF) 351
 hypoxia resistant 898
 Id-1 332
 IE63 727
 IFN- α 873
 IFN- γ -producing cells 748
 ifosfamide 1699
 IL-21 520
 image cytometry 1608
 imaging 1555
 imaging biomarkers 23
 imaging techniques 1555
 imatinib 1219
 imiquimod 1129
 immunohistochemistry 144, 181, 553, 704, 892, 1018, 1157
 immunoinflammation 73
 ImmunoRNase 513
 immunotherapy 115, 513, 852
 immunovisibility 115
 in silico 414
 industry sector 1428
 infectious disease 1670
 inflammation 941, 1113, 1180
 informing patients 1081
 inositol polyphosphates 104
 insulin-like growth factor-binding protein 7 (IGFBP7) 1483
 integrin 541
 interaction 1061
 interferon 1456
 interferon- α 1483
 intergenic and intronic DMR 419
 International Neuroblastoma Risk Group (INRG) 1319
 Internet support 1348
 intraductal 1391
 intravital microscopy 837
 invasion 196, 392, 774, 1052
 ionising radiation 1511
 irinotecan 987
 IVIS 1618
 jointpoint analysis 1411
 kallikrein 1244
 Ki-67 1106, 1391, 1645
 Ki-67 antigen 1753
 kidney cancer 1676
 KIT 1219
 KLK 1244
 KRAS 151, 693, 1254
 KRAS mutation 500
 lapatinib 995
 LASP-1 1645
 L-DOPA decarboxylase 1384
 letrozole 1010, 1235
 leukaemia 620
 linear two-compartment 827
 lipid 403
 liver metastases 255
 liver resection 255
 LMWH 837
 locoregional control 1778
 long-term follow-up 1123, 1405
 luminal 815, 1736
 lung cancer 27, 610, 1180, 1190, 1495, 1533, 1681, 1731
 lymph node positive 1024
 lymphoendothelial retraction 1361
 lymphoma 620
 Lynch syndrome 482
 lysophosphatidic acid 941
 M30 577
 M65 577
 macrophage inhibitory cytokine 1 665
 magnetic resonance spectroscopy 1
 malignancy 727
 malignant melanoma 1157
 malnutrition 966
 mammographic screening 1461
 management 80
 mapatumumab 506
 mass screening 27, 469
 mass spectrometry 1265
 maternal age 1400
 matrix remodelling 392
 MCF-7 cells 316
 MDA-MB-231 cells 316
 MDR1/P-gp 1157
 MeDIP-chip 419
 megestrol acetate 1207
 melanoma 1219, 1707, 1724
 MEPE/OF45 862
 mesothelioma 383, 553
 meta-analysis 301, 428
 metabolism 1
 metalloproteinase 457
 metastasis 403, 561, 602, 867, 1618
 metastatic colorectal cancer 987, 1762
 metastatic models 1555
 metastatic renal cell carcinoma 658
 metastectomy 255
 method validation 1524
 methotrexate 673
 metronomic cyclophosphamide 1207
 mIBG 1319
 microarray 570, 1541
 microenvironment 774, 1533
 microRNA 883, 1174, 1769
 microsatellite instability 482
 microtubule disruptor 316
 migrants: England and Wales 1438
 migration 541, 710, 774
 minimal disease 1319
 minimally invasive surgery 1313
 miR-133a 883
 miR-145 883
 miRNA 376, 1244

- mismatch repair 144, 1068
 mitochondria 1717
 mitotic index 1106
 MKP-1 1137
 MMP 922
 MMP-9 530
 MMR gene promoter
 methylation 482
 modelling 933, 1201
 molecular marker 1137
 mortality 867, 1438
 MRP-1 1157
 MSH3 1068
 MSI status 1762
 MSMB 414
 multimodal 73
 multiple drug resistance 1157
 mutation 693, 1219, 1491
 MutS α 1068
 MutS β 1068
 MyD88 908
 myoglobin 1736
- nadroparin 837
 natural history 213
 NB 685
 necrosis 577
 neoadjuvant 1099
 neoadjuvant chemotherapy
 1600
 neoplasm metastasis 1468
 NETs 1106
 neuroblastoma 615, 1319
 neurosurgery 1213
 NF- κ B 206, 639, 1163
 non-coding RNA 419
 non-invasive biomarkers 1
 non-small cell lung cancer 97,
 1113, 1627
 normalisation 1037
 Notch 351
 Notch1 196
 Noxa 1254
 NS398 765
 NSAIDs 1415
 NU2058 342
 NU6102 342
 NUB1 873
 nutrition 665
- obesity 966
 occupation 1428
 oesophageal adenocarcinoma
 1608
 oesophageal cancer 73, 665,
 1378
 oestrogen receptor 294, 1736
 oestrogen receptor- α 738
 Okuda 748
 older age 1461, 1468
 oocyte 1400
 oral cancer 892
 orthotopic models 1555
 osteoblast 332, 457
 osteoclast 332, 457
 osteonectin 188
 osteoporosis 799
 outcome 1163
- ovarian cancer 87, 495, 704,
 1244
 ovarian cancer stem-like cells
 1276
 overall survival 719, 1769
 oxaliplatin 987, 1254
 oxidative stress 1018
- p27 1235
 p53 719, 1254, 1600, 1645
 paclitaxel 316, 1355
 paediatric 620
 paediatric rhabdomyosarcoma
 227
 Pakistan 1657
 palliative chemotherapy 1207
 PANC-1 cells 583
 pancreatic adenocarcinoma 704
 pancreatic cancer 188, 577, 583,
 1415, 1422
 pancreatic stellate cells 188
 papillary thyroid carcinoma 376
 paternal occupation 615
 pathological response 1099
 patient age 947
 patient-reported outcomes 658
 pazopanib 1371
 PBOX 1474
 PCR 1037
 PDEF 1645
 pemetrexed 553
 Pemphigus vulgaris antigen 181
 peri-operative chemotherapy
 255
 peripheral nerve tumour 1786
 personalised medicine 693
 pertuzumab 134
 pharmacogenetics 1003, 1371
 pharmacokinetic, pharmaco-
 dynamic and efficacy studies
 1555
 pharmacokinetics 673, 1699
 phase I trial 1355, 1699
 phase II trial 68, 506
 Philippines 1411
 phosphoinositide 3-kinase 104
 phosphorylated EGFR 165
 phosphorylation inhibitor 844
 photodynamic therapy 1608
 PI3K 1163, 1491
 PI3K/Akt 196
 pilot studies 1555
 pituitary tumour 1654
 plasma 1174, 1378, 1627
 platelets 1524
 platinum pretreated 1687
 pleural effusion 1180
 pleural fluid 1180
 point counting 1519
 polymorphism 237, 294, 447
 population pharmacokinetic
 827
 portal vein embolisation 1313
 postmenopausal 1201
 postoperative 1327
 PPAR γ 685
 predictive 867, 1201
 pregnane X receptor 1753
- pre-invasive 1391
 prenatal infection 796
 PreTect HPV-Proofer 957
 prevalence 1657
 preventative care 1085
 primary breast cancer 719
 primary care 48, 1085
 primary care delay 947, 1447
 primary systemic therapy 35
 pro-coagulant 73
 prognosis 165, 731, 892, 908,
 922, 952, 1024, 1113, 1327,
 1627, 1692
 prognostic 173, 1032
 proliferation 165, 710, 738
 prophylactic mastectomy 1284
 proportion of tumour 1519
 prospective cohort 610
 prostate biopsy 1335
 prostate cancer 249, 332, 403,
 414, 570, 678, 922, 1163,
 1224, 1491
 prostatic neoplasms 469
 protein kinase B-Akt 104
 proteinchip 1731
 proteomics 1731
 PSA 469, 922, 1335
 P-selectin 602
 PSMB7 361
 psychological distress 1335
 psychological measures 1348
 PTEN 162, 1163, 1778
 PTEN gene loss 678
 PVT1 1618
 pyruvate dehydrogenase 1746
- QLQ-C30 59
 quality of life 27, 59, 1341, 1456
 quality-adjusted survival 19
 quantification 1037
- Rab 392
 race 1676
 radiation 220
 radical hysterectomy 1692
 radiology 285
 radiosensitivity 1511, 1778
 radiotherapy 23, 220, 1555
 randomised controlled trials
 469, 1081, 1207, 1348
 RAS 1137
 RCC 873
 reactive oxygen species 583,
 1018
 real-time PCR 1384
 receptor tyrosine kinase
 inhibitor 658
 RECIST 803
 rectal bleeding 48
 recurrence 570, 1327
 rehabilitation 1348
 relapsed SCLC 629
 REMARK 173
 renal cell cancer 803, 867, 1371,
 1456, 1592, 1676
 replacement, reduction and
 refinement (3Rs) 1555
 reporting guideline 173
- repression 1061
 reproductive factors 1185
 resistance 513, 1724
 response assessment 651
 response criteria 1319
 restraint 1555
 Revised Bethesda Guidelines
 482
 RGZ 685
 rhabdomyosarcoma 1769
 RhoC 196
 ribonucleotide reductase 1361
 risk 220, 1201, 1284, 1294
 risk factors 645, 966
 rituximab 19
 RLB 957
 RNA 916, 1037
 RNA interference 361
 RT-PCR 276
- sarcoma 1207
 sarcoma patients 731
 scirrhous gastric cancer 844,
 898
 Scotland 930
 screening 462, 972, 1335, 1681
 screening recommendations 42
 seasonal variation 1670
 second primary neoplasms
 220
 secondary care referral 947
 SELDI-TOF-MS 1731
 sensitivity and specificity 469
 sentinel lymph nodes 181
 sequencing 243
 serum amyloid A 1731
 serum biomarker 1731
 serum lactate dehydrogenase
 1213
 sex differences 1190
 side population 1276
 Singapore 610
 skin cancer 1661
 skinfold chamber 837
 SMAC-mimetics 1707
 Smad2 844
 small bowel adenocarcinoma
 144
 small cell lung cancer 629
 smoking 610, 1654
 Snail 639, 892
 SNP 414, 1294
 SNP array 1044
 socioeconomic status 719, 1661
 sodium 867
 Sonic hedgehog 738
 sorafenib 68, 268, 495, 1219
 SP 815
 SPARC 188, 530
 SPCs 1190
 spinal tumour 1786
 spiral computed tomography
 27
 spiral CT 1681
 squamous cell carcinoma 262,
 1692
 stability 1524
 Stage IV colorectal cancer 255

- stage of disease 748
STAT3 1592
stathmin1 710
statistical model 1503
stem cells 369
stereotactic radiosurgery 1213
stromal cells 1533
stromal fibroblast 392
STX140 316
subsequent cancer 1397
sunitinib 80, 658, 803, 1699
surgery 1313
survival 665, 678, 1213
survival analysis 173, 1113
survivorship 1348, 1447
synergy 1010, 1224
- T regulatory cells 1129
T315I 1474
tamoxifen 294, 1235
tamoxifen resistance 1503
targeted therapeutics 1
T-cell responses 727
telomere 1300
temsirolimus 1456
TGCT 419
- TGF- β 844
therapeutic HPV vaccination
 1129
therapeutic target 1145
therapy 1555, 1724
thyroid cancer 852
TIC 1618
T-ICs 815
TIMP 922
tissue microarray 922, 1627
TLR4 908
TMPRSS2-ERG fusion 570
TNF- α 639
TOPK 151
TP53 1091
TRAIL 1707
TRAIL-R1 506
transcriptome 243
transformation 436
trastuzumab 134, 513, 520
treatment benefits 1341
treatment toxicity 1341
trends 620, 1661
tumour attenuation 803
tumour biomarkers 1384
tumour burden 1555
- tumour cell glycoconjugates
 602
tumour growth 833
tumour markers 173, 1180,
 1244
tumour models 1555
tumour necrosis factor-related
 apoptosis-inducing ligand
 (TRAIL) 754
tumour progression 1391
tumour regression grade 1600
tumour response 803
tumour suppressor 87
tumourigenesis 1276
tumour-initiating cells 206
type I extrinsic apoptotic
 pathway 754
- UGT1A1 1371
urokinase plasminogen
 activator system 731
uterine serous papillary cancer
 134
- varicella zoster virus 727
vascular disrupting agent 1355
- vascular endothelial growth
 factor 144
VEGF 8, 530, 541, 1699
verotoxin-1 383
VIN 1044
virtual slides 1519
vitamin D 1422
vitamin E 1224
vitamin K3 1224
VSCC 1044
vulva 1044
vulval intraepithelial neoplasia
 (VIN) 1129
- wasting 1541
weight loss 966
whole-genomic microarray 765
women 489, 1654
- XAC 1396-11 97
xenograft 561, 602, 685, 1636
XIAP 97, 1717
- zinc 833
ZOL 1099
zoledronic acid 1010